Neothetics, Inc. (NEOT)

[Lone Wolf]

News! Business update scheduled for next week...Now for those dots...lol.

Buying commenced a couple weeks before today's announcement. Now who would know this was scheduled?

If 'insiders' are taking positions, what's the likelihood the news is bad?

They only have one drug in their pipeline as far as I am aware...it utilizes an 'already FDA approved' compound and, if proven successful, would introduce an efficiency into the marketplace. Looking back over the past year, this fell off a cliff. Hoping now is the time for it to get back up. Low pps already baked in. Float is tiny!

LIPO-202 is a first in class injectable formulation of salmeterol xinafoate, a well-known long-acting ß2-adrenergic receptor agonist used in several FDA-approved drugs, including ADVAIR® for asthma. LIPO-202 is designed to be a locally-injected drug that causes a reduction in the size of fat cells without any effect on nearby tissues. LIPO-202 activates ß2-adrenergic receptors on fat cells, triggering the body’s natural metabolic process of burning fat, leading to spot reduction where injected. LIPO-202 clinical research is focused on reducing undesirable localized areas of fat, including central abdominal fat in non-obese patients (stomach rolls) and submental fat (double chin).